Holen Sie sich die Stockscreener-App
7.91
1.98%
-0.16
Schlusskurs vom Vortag:
$8.07
Offen:
$8.05
24-Stunden-Volumen:
3.20M
Relative Volume:
1.04
Marktkapitalisierung:
$1.66B
Einnahmen:
$557.51M
Nettoeinkommen (Verlust:
$-35.71M
KGV:
-43.94
EPS:
-0.18
Netto-Cashflow:
$15.50M
1W Leistung:
-4.35%
1M Leistung:
-5.27%
6M Leistung:
+2.59%
1J Leistung:
+2.06%
1-Tages-Spanne:
$7.89
$8.10
1-Wochen-Bereich:
$7.89
$8.315
52-Wochen-Spanne:
$6.015
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Vergleichen Sie BCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.91 | 1.68B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
AQR Capital Management LLC Purchases 362,175 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Parkman Healthcare Partners LLC Has $7.50 Million Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
60,600 Shares in BioCryst Pharmaceuticals, Inc. $BCRX Bought by Exome Asset Management LLC - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $16.70 Consensus Target Price from Brokerages - MarketBeat
Boothbay Fund Management LLC Cuts Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Trexquant Investment LP Has $2.92 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals, Inc. $BCRX Shares Bought by Graham Capital Management L.P. - MarketBeat
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Northern Trust Corp - MarketBeat
BioCryst Pharmaceuticals Inc. Pullback Analyzed — Is It Time to ExitWeekly Trade Report & High Conviction Trade Alerts - beatles.ru
Is BioCryst Pharmaceuticals Inc. affected by consumer sentimentJuly 2025 Outlook & Fast Entry Momentum Alerts - 뉴스영
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 Revenue Soars 49%, Hits Record $163.4 Million on ORLADEYO Surge - MSN
Ieq Capital LLC Buys 93,267 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Will BioCryst Pharmaceuticals Inc. outperform its industry peersEarnings Recap Summary & Safe Entry Zone Tips - beatles.ru
Panagora Asset Management Inc. Sells 306,402 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Alkeon Capital Management LLC Buys 120,199 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Forecasting BioCryst Pharmaceuticals Inc. price range with options dataJuly 2025 Closing Moves & High Return Stock Watch Alerts - Newser
Is a relief rally coming for BioCryst Pharmaceuticals Inc. holdersJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - Newser
Understanding BioCryst Pharmaceuticals Inc.’s price movementProduct Launch & Advanced Technical Signal Analysis - Newser
Is BioCryst Pharmaceuticals Inc. forming bullish engulfing patternsJuly 2025 Market Mood & Growth Focused Entry Point Reports - خودرو بانک
Does BioCryst Pharmaceuticals Inc. stock reflect fundamentalsJuly 2025 Levels & Precise Swing Trade Alerts - خودرو بانک
Can technical indicators confirm BioCryst Pharmaceuticals Inc.’s reversalJuly 2025 Breakouts & High Yield Equity Trading Tips - Newser
BioCryst Pharmaceuticals Stock (BCRX) Opinions on Q2 Revenue Surge and Conference Insights - Quiver Quantitative
BioCryst at Cantor Global Healthcare Conference: Strategic Growth and Opportunities - Investing.com Canada
BioCryst Pharmaceuticals: A High-Growth Biotech Play with a Strong Pipeline and Strategic Financial Moves - AInvest
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 09 - MarketScreener
Walleye Capital LLC Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Order flow analysis tools used on BioCryst Pharmaceuticals Inc.2025 Year in Review & Verified Stock Trade Ideas - Newser
Can BioCryst Pharmaceuticals Inc. stock double in the next yearProfit Target & Smart Investment Allocation Insights - خودرو بانک
Is BioCryst Pharmaceuticals Inc. forming a breakout pattern2025 Trading Volume Trends & Consistent Profit Focused Trading Strategies - خودرو بانک
Will BioCryst Pharmaceuticals Inc. see short term momentum2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - Newser
What are BioCryst Pharmaceuticals Inc.’s earnings expectationsJuly 2025 Momentum & Fast Entry Momentum Trade Alerts - خودرو بانک
Can you recover from losses in BioCryst Pharmaceuticals Inc.Chart Signals & Smart Money Movement Tracker - Newser
Published on: 2025-09-04 04:25:22 - Newser
Kodai Capital Management LP Invests $3.52 Million in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Is BioCryst Pharmaceuticals Inc. still worth holding after the dipGold Moves & Detailed Earnings Play Alerts - Newser
Best data tools to analyze BioCryst Pharmaceuticals Inc. stockWeekly Volume Report & Weekly High Conviction Ideas - Newser
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
71,400 RSUs and 36,700 Stock Options: BioCryst's Latest Employee Compensation Package Details - Stock Titan
Applying Elliott Wave Theory to BioCryst Pharmaceuticals Inc.Gap Up & Daily Profit Maximizing Trade Tips - Newser
What to do if you’re stuck in BioCryst Pharmaceuticals Inc.Earnings Risk Report & Expert Approved Trade Ideas - Newser
BioCryst Pharmaceuticals Inc. stock prediction for this weekEarnings Growth Summary & AI Driven Stock Movement Reports - Newser
How to read the order book for BioCryst Pharmaceuticals Inc.Trade Analysis Report & Daily Growth Stock Investment Tips - Newser
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
Is BioCryst Pharmaceuticals Inc. a defensive stockJuly 2025 Analyst Calls & Stock Portfolio Risk Management - خودرو بانک
Fibrodysplasia Ossificans Market to Experience Notable Growth in Forecast Span by 2032, DelveInsight Predicts | Ipsen, Regeneron Pharma, Biocryst - Barchart.com
Will BioCryst Pharmaceuticals Inc. benefit from rising consumer demandMarket Performance Report & Risk Controlled Stock Pick Alerts - خودرو بانک
How to build a custom watchlist for BioCryst Pharmaceuticals Inc.July 2025 Decliners & Expert Verified Stock Movement Alerts - Newser
Custom watchlist performance reports with BioCryst Pharmaceuticals Inc.2025 Support & Resistance & Daily Risk Controlled Trade Plans - Newser
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.67%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):